Related Experiment Video
Updated: Jun 14, 2026

An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells
Published on: August 15, 2012
Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
Claudia Demarta-Gatsi1, Nicole Andenmatten1, María-Belén Jiménez-Díaz2
1Medicines for Malaria Venture, Geneva, Switzerland.
Developing new antimalarial drug combinations is crucial for malaria control. A humanized mouse model (PfalcHuMouse) effectively evaluates drug efficacy, identifying parasite killing as the key metric for optimal combination selection.
Area of Science:
- * Infectious Diseases
- * Parasitology
- * Pharmacology
Background:
- * Urgent need for novel antimalarial drug combinations to combat drug-resistant Plasmodium falciparum.
- * Existing treatments face challenges due to emerging parasite resistance.
- * Malaria control and eradication efforts require innovative therapeutic strategies.
Purpose of the Study:
- * Evaluate a standardized humanized mouse model (PfalcHuMouse) for selecting optimal antimalarial drug combinations.
- * Compare different therapeutic response variables for assessing drug combination efficacy in vivo.
- * Determine the most reliable method for estimating individual drug contributions within combinations.
Main Methods:
- * Utilized a robust and reproducible Plasmodium falciparum (Pf) replication model in humanized mice (PfalcHuMouse).
- * Compared parasite clearance, recrudescence (parasite regrowth), and cure as therapeutic response variables.
- * Formalized and validated the Day of Recrudescence (DoR) as a quantitative measure of parasite burden.
- * Employed multivariate statistical modeling and pharmacokinetic/pharmacodynamic (PK/PD) analysis.
Main Results:
- * Demonstrated robust and reproducible P. falciparum replication in the PfalcHuMouse model.
- * Established a log-linear relationship between the Day of Recrudescence (DoR) and parasite numbers.
- * Found that measuring parasite killing (cure) as a function of drug exposure is essential for estimating individual drug contributions.
- * Identified ferroquine plus artefenomel and piperaquine plus artefenomel combinations in historical data.
Conclusions:
- * The PfalcHuMouse model is a validated tool for evaluating antimalarial drug combinations.
- * Parasite killing (cure) is the most informative variable for assessing drug contributions in vivo.
- * Pharmacometric modeling using parasite killing data aids in selecting optimal antimalarial drug combinations.
- * This approach supports malaria control and eradication strategies.
More Related Videos
09:02An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
Published on: February 17, 2014
08:14An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection
Published on: October 6, 2015